News
ATAI
4.090
+2.25%
0.090
BUZZ-Psychedelic drug developers rise after CBS report Trump backs more research
Reuters · 4h ago
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug
Seeking Alpha · 5h ago
Trump to sign order on psychedelic used for PTSD, CBS News says
TipRanks · 5h ago
Atai Beckley CEO joins Needham Virtual Healthcare Conference fireside chat
PUBT · 2d ago
Weekly Report: what happened at ATAI last week (0406-0410)?
Weekly Report · 3d ago
Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO
NASDAQ · 6d ago
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
TipRanks · 04/09 15:00
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD
Seeking Alpha · 04/08 19:54
AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response
Benzinga · 04/08 14:21
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response In TRD
NASDAQ · 04/08 11:35
AtaiBeckley's BPL-003 Achieved Rapid And Sustained Reductions in Treatment-Resistant Depression Scores, Phase 3 Initiation On Track For Q2 2026
Benzinga · 04/08 10:10
AtaiBeckley announces peer-reviewed Phase 2a results of BPL-003 study
TipRanks · 04/08 10:07
AtaiBeckley says BPL-003 hits 67% Day-2 response in Phase 2a TRD study
Reuters · 04/08 10:01
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT)
TipRanks · 04/08 09:30
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
Barchart · 04/08 05:00
Weekly Report: what happened at ATAI last week (0330-0403)?
Weekly Report · 04/06 10:26
Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
TipRanks · 04/02 13:55
Weekly Report: what happened at ATAI last week (0323-0327)?
Weekly Report · 03/30 10:26
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
Benzinga · 03/27 17:28
ATAI Life Sciences Price Target Announced at $12.00/Share by Deutsche Bank
Dow Jones · 03/27 14:28
More
Webull provides a variety of real-time ATAI stock news. You can receive the latest news about Atai Beckley Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATAI
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.